STOCK TITAN
  1. Home
  2. Sec-filings
  3. IONS
  4. [Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity

Ionis (NASDAQ: IONS) EVP Kordasiewicz sells 60,846 shares after option exercises

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ionis Pharmaceuticals EVP and Chief Development Officer Holly B. Kordasiewicz reported an exercise-and-sell transaction in Ionis common stock. On June 12, 2026, she sold a total of 60,846 shares in open-market sales, including 19,842 shares at a weighted average price of $74.0503 per share and 41,004 shares at a weighted average price of $73.0934 per share.

The sales were made under a pre-arranged Rule 10b5-1 Trading Plan adopted on March 13, 2026, meaning the trades were scheduled in advance. On the same date, she exercised non-qualified stock options covering a total of 60,846 shares of common stock at exercise prices of $32.60, $56.78, and $60.89 per share, converting derivative awards into shares that were then largely sold for liquidity.

Positive

  • None.

Negative

  • None.
Insider Kordasiewicz Holly B.
Role EVP, Chief Development Officer
Sold 60,846 shs ($4.47M)
Type Security Shares Price Value
Exercise Non-Qualified Stock Option (right to buy) 12,000 $0.00 --
Exercise Non-Qualified Stock Option (right to buy) 19,895 $0.00 --
Exercise Non-Qualified Stock Option (right to buy) 7,951 $0.00 --
Exercise Non-Qualified Stock Option (right to buy) 21,000 $0.00 --
Exercise Common Stock 7,951 $60.89 $484K
Exercise Common Stock 21,000 $60.89 $1.28M
Exercise Common Stock 12,000 $32.60 $391K
Exercise Common Stock 19,895 $56.78 $1.13M
Sale Common Stock 41,004 $73.0934 $3.00M
Sale Common Stock 19,842 $74.0503 $1.47M
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 0 shares (Direct, null); Common Stock — 30,409 shares (Direct, null)
Footnotes (1)
  1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.68 to $73.67 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.735 to $74.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Total shares sold 60,846 shares Common stock sold in open-market transactions on June 12, 2026
Sale block 1 41,004 shares at $73.0934/share Weighted average price for one sale block of common stock
Sale block 2 19,842 shares at $74.0503/share Weighted average price for second sale block of common stock
Option exercises 60,846 shares Common shares acquired via option exercises on June 12, 2026
Exercise price 1 $32.60/share Exercise price of one tranche of non-qualified stock options
Exercise price 2 $56.78/share Exercise price of second tranche of non-qualified stock options
Exercise price 3 $60.89/share Exercise price of additional non-qualified stock options
Net buy/sell shares 60,846 shares net sold Net share change across all reported buy/sell transactions
Rule 10b5-1 Trading Plan financial
"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option (right to buy) financial
"Non-Qualified Stock Option (right to buy) with an underlying security of Common Stock"
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kordasiewicz Holly B.
(Last)(First)(Middle)
2855 GAZELLE COURT
(Street)
CARLSBAD CALIFORNIA 92010
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Chief Development Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/12/2026M7,951A$60.8930,409D
Common Stock06/12/2026M21,000A$60.8951,409D
Common Stock06/12/2026M12,000A$32.663,409D
Common Stock06/12/2026M19,895A$56.7883,304D
Common Stock06/12/2026S41,004(1)D$73.0934(2)42,300D
Common Stock06/12/2026S19,842(1)D$74.0503(3)22,458D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)$32.606/12/2026M12,00001/03/202301/02/2032Common Stock12,000$0.00D
Non-Qualified Stock Option (right to buy)$56.7806/12/2026M19,89501/04/202201/03/2028Common Stock19,895$0.00D
Non-Qualified Stock Option (right to buy)$60.8906/12/2026M7,95101/02/202101/01/2027Common Stock7,951$0.021,000D
Non-Qualified Stock Option (right to buy)$60.8906/12/2026M21,00001/02/202101/01/2027Common Stock21,000$0.00D
Explanation of Responses:
1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.68 to $73.67 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.735 to $74.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
By: Patrick R. O'Neil, attorney-in-fact For: Holly Kordasiewicz06/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Ionis Pharmaceuticals (IONS) report for Holly B. Kordasiewicz?

Holly B. Kordasiewicz reported an exercise-and-sell transaction in Ionis common stock. She exercised options for 60,846 shares, then sold 60,846 shares in open-market trades on June 12, 2026, as disclosed in the Form 4.

How many Ionis Pharmaceuticals (IONS) shares did Holly B. Kordasiewicz sell and at what prices?

She sold 60,846 Ionis common shares in total. This included 41,004 shares at a weighted average price of $73.0934 and 19,842 shares at a weighted average price of $74.0503, with individual trades spanning stated intraday price ranges.

Were Holly B. Kordasiewicz’s Ionis (IONS) stock sales made under a Rule 10b5-1 plan?

Yes. The Form 4 states that the shares sold were pursuant to a Rule 10b5-1 Trading Plan adopted by Holly B. Kordasiewicz on March 13, 2026, indicating the sales were pre-scheduled rather than discretionary market-timing decisions.

What stock options did Holly B. Kordasiewicz exercise in Ionis Pharmaceuticals (IONS)?

She exercised non-qualified stock options for 60,846 shares of Ionis common stock. The exercised options carried exercise prices of $32.60, $56.78, and $60.89 per share, converting derivative awards into common shares on June 12, 2026.

What price ranges applied to the Ionis (IONS) insider stock sales reported by Holly B. Kordasiewicz?

The Form 4 notes that weighted average prices reflect multiple trades. One sale block occurred between $72.68 and $73.67 per share, and another between $73.735 and $74.28 per share, with full trade-by-trade details available upon request.